Sonnet BioTherapeutics Stock Plunges 15.66% Amid Capital Raise

From Teenage Sweethearts to Pioneers in Cancer Therapy: The Story Behind Creative BioTherapeutics

Prof. Johan Kuiper will retire as of November 1st 2024 after 40 years of research and education

3 Hot New Biotech Launches For Your Sweltering Summer

LabGenius cements £35M to advance AI-powered antibody discovery platform

LabGenius to create molecules with increase in tumor killing ability